1. Academic Validation
  2. Modification of olivomycin A at the side chain of the aglycon yields the derivative with perspective antitumor characteristics

Modification of olivomycin A at the side chain of the aglycon yields the derivative with perspective antitumor characteristics

  • Bioorg Med Chem. 2011 Dec 15;19(24):7387-93. doi: 10.1016/j.bmc.2011.10.055.
Anna N Tevyashova 1 Alexander A Shtil Eugenia N Olsufyeva Yury N Luzikov Marina I Reznikova Lyubov G Dezhenkova Elena B Isakova Vladimir M Bukhman Nikita A Durandin Alexander M Vinogradov Vladimir A Kuzmin Maria N Preobrazhenskaya
Affiliations

Affiliation

  • 1 Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 B. Pirogovskaya Street, Moscow 119021, Russian Federation.
Abstract

A novel way of chemical modification of the Antibiotic olivomycin A (1) at the side chain of the aglycon moiety was developed. Interaction of olivomycin A with the sodium periodate produced the key acid derivative olivomycin SA (2) in 86% yield. This acid was used in the reactions with different amines in the presence of benzotriazol-1-yl-oxy-trispyrrolidino-phosphonium hexafluorophosphate (PyBOP) or diphenylphosphoryl azide (DPPA) to give corresponding amides. Whereas olivomycin SA was two orders of magnitude less cytotoxic than the parent Antibiotic, the amides of 2 demonstrated a higher cytotoxicity. In particular, N,N-dimethylaminoethylamide of olivomycin SA showed a pronounced antitumor effect against transplanted experimental lymphoma and melanoma and a remarkably high binding constant to double stranded DNA. The therapeutic effects of this derivative were achievable at tolerable concentrations, suggesting that modifications of the aglycon's side chain, namely, its shortening to methoxyacetic residue and blocking of free carboxyl group, are straightforward for the design of therapeutically applicable derivatives of olivomycin A.

Figures
Products